title: [Interferon-gamma. Therapy of recurrent furunculosis in HIV infections].
abstract: Four HIV-antibody-positive patients in stages CDC II to CDC IV C2 with furuncles that had so far proved refractory to treatment were successfully treated with systemic application of recombined gamma-interferon, 50 micrograms s.c. on days 1, 2 and 3 of the first week with a new cycle after 3 weeks. A significant clinical improvement was seen in all patients after three to five cycles. Side-effects of therapy with gamma-interferon were similar to the symptoms of influenza and improved during therapy. No changes in immunological parameters and white blood cells counts were observed. The general condition of the patients improved or remained unchanged. A few weeks after discontinuation of therapy two patients relapsed, but they were again successfully treated with gamma-interferon.
authors.affiliation: Dermatologische Klinik und Poliklinik, Ludwig-Maximilians-Universität, München.
authors.forename: E
authors.initials: E
authors.lastname: Thoma-Greber
authors.forename: M
authors.initials: M
authors.lastname: Fröschl
authors.forename: W
authors.initials: W
authors.lastname: Stolz
authors.forename: M
authors.initials: M
authors.lastname: Landthaler
authors.forename: G
authors.initials: G
authors.lastname: Plewig
mesh_terms: D017088:AIDS-Related Opportunistic Infections / Q000276:immunology / Q000628:therapy*; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000276:immunology; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005667:Furunculosis / Q000276:immunology / Q000628:therapy*; D006716:Homosexuality; D006801:Humans; D007279:Injections, Subcutaneous; D007371:Interferon-gamma / Q000009:adverse effects / Q000627:therapeutic use*; D007958:Leukocyte Count; D008297:Male; D008875:Middle Aged; D011994:Recombinant Proteins; D015819:Substance Abuse, Intravenous / Q000150:complications
chemical_list: D011994:Recombinant Proteins; D007371:Interferon-gamma
vernacular_title: Interferon-Gamma. Therapie von rezidivierenden Furunkulosen bei HIV-Infektion.